Premium
P4–366: ZT–1 for the symptomatic treatment of mild to moderate Alzheimer disease (AD): Preliminary results of a multicenter, randomised, double–blind, placebo and active controlled phase II study
Author(s) -
Tamchès Emmanuel,
Orgogozo Jean-Marc,
Wilkinson David,
Todorova Yancheva Stefka,
Gagiano Carlo,
Grosgurin Pierre,
Porchet Hervé,
Scalfaro Pietro
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2107
Subject(s) - donepezil , placebo , medicine , adverse effect , acetylcholinesterase , dementia , clinical trial , phases of clinical research , gastroenterology , pharmacology , disease , pathology , chemistry , biochemistry , alternative medicine , enzyme
IL-1 peaked at the 2 hour after reperfusion and was significantly lower in the high CGE dosage (531.8 151.1 ) than that (687.6 116.9) in the model group (P 0.01), but not significantly different from IL-1ra group(574.6 56.7). The expression of CRF peaked at the 12 hour after reperfusion and was significantly lower in a high CGE dosage (401.1 76.8) than that (428.8 38.1) in the model group at the 12 hour following cerebral ischemia-reperfusion (P 0.01), but not significantly different from IL-1ra group (408.3 81.7). Conclusions: Such data suggest that CGE has the function of inhibiting up-adjusted expression of IL-1 and CRF protein following cerebral ischemia-reperfusion, act as IL-1ra preventing and treating neurons damage in hippocampus in rat with VaD.